Keith Tapper

Stock Analyst at BMO Capital

(2.89)
# 1,760
Out of 5,044 analysts
6
Total ratings
66.67%
Success rate
36.47%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Keith Tapper

Neurogene
Apr 14, 2025
Maintains: Outperform
Price Target: $45$16
Current: $30.96
Upside: -48.32%
Taysha Gene Therapies
Jun 27, 2024
Initiates: Outperform
Price Target: $5
Current: $4.99
Upside: +0.20%
ACADIA Pharmaceuticals
Jun 27, 2024
Initiates: Outperform
Price Target: $31
Current: $22.62
Upside: +37.05%